Evidence map›Paper›PMID 24700501›Full record

ArticleHepatology (Baltimore, Md.)2014

Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.

Runping Liu, Renping Zhao, Xiqiao Zhou, Xiuyin Liang, Deanna J W Campbell, Xiaoxuan Zhang, Luyong Zhang, Ruihua Shi, Guangji Wang, William M Pandak and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 1 synthesis or guideline pooled it, 178 citations in OpenAlex.

  1. Pooled it
  2. Bile acid signaling in health and disease.Molecular biomedicine · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Runping LiuDepartment of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond, VA; Key Laboratory of New Drug Screen and Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Renping Zhao
Xiqiao Zhou
Xiuyin Liang
Deanna J W Campbell
Xiaoxuan Zhang
Luyong Zhang
Ruihua Shi
Guangji Wang
William M Pandak
Alphonse E Sirica
Phillip B Hylemon
Huiping Zhou
Virginia Commonwealth University · USNanjing Medical University · CNChina Pharmaceutical University · CN

Funding

VCU Neuroscience Center Core GrantP30NS047463 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI POVLISHOCK, JOHN T · 2003 to 2013
$5.0M
ALTERED GROWTH FACTOR PATHWAYS IN BILLIARY CANCERR01CA083650 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SIRICA, ALPHONSE E · 2000 to 2017
$4.4M
Regulation of Hepatic SphK2 by Bile Acids: Effects on Lipid MetabolismR01DK057543 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HYLEMON, PHILLIP B, ZHOU, HUIPING ROSE · 2001 to 2015
$4.4M
HEPATIC OVAL CELLS IN CULTURE AND IN VIVOR01CA039225 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SIRICA, ALPHONSE E · 1986 to 2011
$3.1M
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in CholestasisR01DK104893 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HYLEMON, PHILLIP B, ZHOU, HUIPING ROSE · 2016 to 2020
$2.0M
Role of Cholesterol in Non Alcoholic Fatty LiverI01BX000197 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI PANDAK, WILLIAM M · 2009 to 2021
–
BLRD VA I01 BX000197NCI NIH HHS 5R01CA-39225NCI NIH HHS R01 CA039225NCI NIH HHS R01 CA083650NCI NIH HHS R01CA-83650NIDDK NIH HHS R01 DK-057543NIDDK NIH HHS R01 DK057543NIDDK NIH HHS R01 DK104893NINDS NIH HHS 5P30NS047463
6 · The paper itself

Abstract

unlabelledCholangiocarcinoma (CCA) is an often fatal primary malignancy of the intra- and extrahepatic biliary tract that is commonly associated with chronic cholestasis and significantly elevated levels of primary and conjugated bile acids (CBAs), which are correlated with bile duct obstruction (BDO). BDO has also recently been shown to promote CCA progression. However, whereas there is increasing evidence linking chronic cholestasis and abnormal bile acid profiles to CCA development and progression, the specific mechanisms by which bile acids may be acting to promote cholangiocarcinogenesis and invasive biliary tumor growth have not been fully established. Recent studies have shown that CBAs, but not free bile acids, stimulate CCA cell growth, and that an imbalance in the ratio of free to CBAs may play an important role in the tumorigenesis of CCA. Also, CBAs are able to activate extracellular signal-regulated kinase (ERK)1/2- and phosphatidylinositol-3-kinase/protein kinase B (AKT)-signaling pathways through sphingosine 1-phosphate receptor 2 (S1PR2) in rodent hepatocytes. In the current study, we demonstrate S1PR2 to be highly expressed in rat and human CCA cells, as well as in human CCA tissues. We further show that CBAs activate the ERK1/2- and AKT-signaling pathways and significantly stimulate CCA cell growth and invasion in vitro. Taurocholate (TCA)-mediated CCA cell proliferation, migration, and invasion were significantly inhibited by JTE-013, a chemical antagonist of S1PR2, or by lentiviral short hairpin RNA silencing of S1PR2. In a novel organotypic rat CCA coculture model, TCA was further found to significantly increase the growth of CCA cell spheroidal/"duct-like" structures, which was blocked by treatment with JTE-013.

conclusionOur collective data support the hypothesis that CBAs promote CCA cell-invasive growth through S1PR2.

Indexed as

AnimalsBile Acids and SaltsBile Duct NeoplasmsBile Ducts, IntrahepaticCarcinogenesisCell Line, TumorCell MovementCell ProliferationCholangiocarcinomaCoculture TechniquesHumansNeoplasm InvasivenessRatsReceptors, LysosphingolipidRNA InterferenceRNA, Small InterferingBile Acids and SaltsReceptors, LysosphingolipidRNA, Small InterferingS1PR2 protein, humanSphingosine-1-Phosphate Receptors

Identifiers

PMID24700501
PMCPMC4141906
OpenAlexW2136466723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.